난소암 치료제 시장 예측 : 산업 규모, 점유율, 동향, 기회, 약제 클래스별, 종양 유형별, 유통 채널별, 지역별, 경쟁 구도(2021-2031년)

The Global Ovarian Cancer Drugs Market will grow from USD 4.32 Billion in 2025 to USD 6.36 Billion by 2031 at a 6.66% CAGR. Ovarian cancer drugs encompass a diverse range of pharmacological interventions, including platinum-based chemotherapies, poly (ADP-ribose) polymerase (PARP) inhibitors, and angiogenesis inhibitors, designed to treat malignancies of the ovaries, fallopian tubes, and peritoneum. The market is primarily driven by the increasing global incidence of ovarian cancer and the growing geriatric population, as age constitutes a significant risk factor for the disease.

Key Market Drivers

Advancements in PARP inhibitors and targeted therapeutics are fundamentally altering the clinical management of ovarian cancer by offering precise mechanisms of action that improve patient outcomes compared to traditional chemotherapy. The market is witnessing a significant shift towards antibody drug conjugates and maintenance therapies that target specific biomarkers like folate receptor alpha. This transition is exemplified by the commercial success of recently approved agents which are rapidly capturing market share.

Key Market Challenges

The prohibitive cost associated with novel targeted therapies and immunotherapies constitutes a substantial impediment to the growth of the global ovarian cancer drugs market. High pricing structures for these advanced regimens lead to significant financial toxicity, forcing healthcare payers to implement stringent reimbursement policies that often restrict patient eligibility to a narrow subset of the population. In many regions, particularly developing economies, the resulting high out-of-pocket expenses effectively place these life-extending treatments out of reach for many individuals.

Key Market Trends

The development of novel therapies for platinum-resistant disease is increasingly focusing on distinct histological subtypes rather than treating resistant cases as a monolithic group. This trend is exemplified by the emergence of targeted inhibitors for low-grade serous ovarian cancer (LGSOC), a rare and chemo-resistant form of the disease driven by the RAS/MAPK pathway. Unlike broad-spectrum chemotherapy or antibody-drug conjugates, these regimens utilize RAF/MEK clamps to disrupt oncogenic signaling in tumors harboring KRAS mutations.

Key Market Players

• AstraZeneca, Plc
• GlaxoSmithKline, Plc
• Merck & Co.
• Clovis Oncology, Inc.
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Co.
• Eli Lilly and Company
• Amgen Inc.
• C.H. Boehringer Sohn Ko. KG
• Novartis AG

Report Scope:

In this report, the Global Ovarian Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Ovarian Cancer Drugs Market, By Tumor Type:

• Epithelial Ovarian Cancer
• Ovarian Low Malignant Potential Tumor
• Germ Cell Tumor
• Sex Cord-Stromal Tumor

Ovarian Cancer Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Ovarian Cancer Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Ovarian Cancer Drugs Market.

Available Customizations:

Global Ovarian Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Ovarian Cancer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Ovarian Cancer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tumor Type
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Ovarian Cancer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tumor Type
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Canada Ovarian Cancer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tumor Type
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Mexico Ovarian Cancer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tumor Type
      • 6.3.3.2.2. By Distribution Channel

7. Europe Ovarian Cancer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tumor Type
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Ovarian Cancer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tumor Type
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. France Ovarian Cancer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tumor Type
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Ovarian Cancer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tumor Type
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Ovarian Cancer Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tumor Type
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Ovarian Cancer Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tumor Type
      • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Ovarian Cancer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tumor Type
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Ovarian Cancer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tumor Type
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Ovarian Cancer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tumor Type
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. Japan Ovarian Cancer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tumor Type
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. South Korea Ovarian Cancer Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Tumor Type
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Ovarian Cancer Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Tumor Type
      • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Ovarian Cancer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tumor Type
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Ovarian Cancer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tumor Type
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. UAE Ovarian Cancer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tumor Type
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. South Africa Ovarian Cancer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tumor Type
      • 9.3.3.2.2. By Distribution Channel

10. South America Ovarian Cancer Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tumor Type
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Ovarian Cancer Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tumor Type
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Colombia Ovarian Cancer Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tumor Type
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. Argentina Ovarian Cancer Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tumor Type
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Ovarian Cancer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca, Plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. GlaxoSmithKline, Plc
• 15.3. Merck & Co.
• 15.4. Clovis Oncology, Inc.
• 15.5. F. Hoffmann-La Roche AG
• 15.6. Bristol-Myers Squibb Co.
• 15.7. Eli Lilly and Company
• 15.8. Amgen Inc.
• 15.9. C.H. Boehringer Sohn Ko. KG
• 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer